Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas-Reference-Cited by-同舟云学术

Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas

Published:2016-08-17 Issue:8 Volume:11 Page:e0161438
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Pinto Pedro,Peixoto Ana,Santos Catarina,Rocha Patrícia,Pinto Carla,Pinheiro Manuela,Leça Luís,Martins Ana Teresa,Ferreira Verónica,Bartosch Carla,Teixeira Manuel R.^ORCID

Funder

Fundação para a Ciência e a Tecnologia

Núcleo Regional do Norte da Liga Portuguesa Contra o Cancro

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference38 articles.

1. BRCA1 and BRCA2: 1994 and beyond;SA Narod;Nat Rev Cancer,2004

2. Clinical practice. Management of an inherited predisposition to breast cancer;M Robson;N Engl J Med,2007

3. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE;N Mavaddat;J Natl Cancer Inst,2013

4. Founder mutations in BRCA1 and BRCA2 genes;R Ferla;Ann Oncol,2007

5. The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry;A Peixoto;Clin Genet,2015

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Targets and Therapies for Ampullary Cancer;Journal of the National Comprehensive Cancer Network;2024-06

2. Using Portuguese BRCA pathogenic variation as a model to study the impact of human admixture on human health;BMC Genomics;2024-04-27

3. Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review;Cancers;2023-12-21

4. Ampullary Adenocarcinoma: A Review of the Mutational Landscape and Implications for Treatment;Cancers;2023-12-09

5. Ampulla of Vater carcinoma: advancement in the relationships between histological subtypes, molecular features, and clinical outcomes;Frontiers in Oncology;2023-05-18